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This high efficacy is accompanied by a new set of side ef-
fects. In the pivotal phase III mRCC trial, updated data 
indicates that 21% of sunitinib-treated patients experi-
enced a reversible decline in left ventricular ejection frac-
tion to below normal  [2] . Although we were aware of car-
diac toxicity, we had to experience a surprising course of 
a patient which we report here.
 Case Report 
 A 74-year-old male patient was admitted with bilateral dis-
seminated lung metastases and mediastinal and hilar lymph node 
metastases from clear cell RCC. Recurrent RCC was also suspect-
ed in the left kidney. The initial diagnosis of RCC was made 5 
years prior to detection of metastases when right-sided radical 
nephrectomy including lymphadenectomy and adrenalectomy 
was performed and revealed pT3a (7 cm) pN0 cM0 G2 R0 clear 
cell RCC. Surgery was complicated by perioperative resuscitation 
due to ventricular tachyarrhythmia. Three years after nephrec-
tomy the patient suffered from myocardial infarction and con-
secutively developed dilatative cardiomyopathy. He was given a 
pacer (AICD). Further anamnesis included chronic pulmonary 
obstructive disease and insulin-independent diabetes mellitus. 
The patient was in a good clinical condition with a Karnofsky in-
dex of 80% and occasionally worked as a gardener.
 Prior to systemic therapy, MUGA echocardiography was per-
formed which revealed a dilated left ventricle with a reduction of 
the ejection fraction to 42%. The dorsal wall was hypokinetic with 
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 Abstract 
 A 74-year-old man with metastatic renal cell carcinoma and 
a history of cardiac failure was treated with sunitinib ma-
late. MUGA echocardiography could not detect a relevant 
change in the ejection fraction although the clinical situa-
tion of the patient worsened dramatically. The only param-
eter to hint at the deteriorated cardiac function was plasma 
N-terminal pro-brain natriuretic peptide (BNP). Finally, the 
patient died after only one cycle of sunitinib treatment. We 
propose to prospectively include BNP for the early detection 
of cardiovascular decompensation in high-risk patients. Fu-
ture studies concerning the relevance of BNP in drug-related 
cardiotoxicity are urgently needed. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Sunitinib malate has demonstrated high efficacy in 
metastatic renal cell carcinoma (mRCC). Compared to 
interferon therapy, progression-free survival was dou-
bled with a trend towards improved overall survival  [1] . 
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a small thrombus of 2.6  ! 0.6 cm, primarily overlooked in the 
initial computed tomography. Further grade I insufficiency of the 
mitral and tricuspid valves was seen.
 The patient was 170 cm tall and weighed 69 kg. Initial blood 
pressure was 105/70 mm Hg. Medication consisted of ramipril 2.5 
mg b.i.d., bisoprolol 2.5 mg b.i.d., furosemide 20 mg o.d., aspirin 
100 mg o.d., and pravastatin 20 mg o.d. Initial serum chemistry 
showed normal values for sodium, potassium, calcium, BNP 
(6,700 pg/ml), CRP, creatinine, AST, ALT, AP, LDH, albumin, se-
rum protein and TSH. Blood chemistry showed a lowered hemo-
globin level of 13.6 g/dl with normal values for thrombocytes and 
leukocytes.
 The situation was intensively discussed with the patient and 
he was started on sunitinib with the knowledge of an increased 
risk for a cardiac event. Therapy was initially well-tolerated with-
out development of hypertension. The only adverse event seen 
was discrete peripheral edema that was treated with a slight in-
crease of the diuretic therapy. In week 4 of the first treatment 
course, the patient’s general condition worsened with complete 
recovery in the planned 2-week therapeutic break of sunitinib 
therapy.
 After one cycle, MUGA echocardiography was controlled and 
revealed an ejection fraction of 36%. The preexisting thrombus 
had grown to 3.0  ! 3.2 cm ( fig. 1 ). In serum chemistry, plasma 
N-terminal pro-brain natriuretic peptide (BNP) had increased to 
27,000 pg/ml with all other parameters unchanged. To prevent 
further thrombosis the patient was started on coumarin with an 
INR of 2.0.
 Three days after restarting sunitinib therapy the patient’s gen-
eral condition deteriorated and he had to be admitted to the ward. 
Progressive cardiac failure with central venous congestion devel-
oped. Consecutively, liver-compensated failure developed and re-
nal function deteriorated without the need for dialysis. BNP in-
creased to 45,000 pg/ml. Sunitinib was immediately withdrawn. 
No deep vein thrombosis was seen but the left ventricular throm-
bus had grown to 3.5  ! 4.0 cm without a change in ejection frac-
tion. After a further radiological diagnostic evaluation, no pro-
gression of the disease was seen. The patient died 8 weeks after 
initiation of sunitinib therapy with only one cycle and 3 days of 
systemic treatment due to progressive heart failure.
 Discussion 
 Cardiac side effects are commonly described with ty-
rosine-kinase inhibition therapy for mRCC, some of 
which may be fatal. In the first publication on sunitinib 
efficacy as a second-line indication  [3] , 1 of 106 patients 
was suspected to have died from a cardial event, but no 
further information on this incident was obtainable. 
Thus, study protocols performed with tyrosine-kinase 
inhibitor drugs thoroughly control electrocardiograms 
and echocardiography to detect changes in the ejection 
fraction.
 In a retrospective analysis at Stanford, 7 of 48 patients 
(15%) developed grade 3/4 heart failure. Of these patients, 
3 had persistent cardiac dysfunction after discontinua-
tion of sunitinib and initiation of heart failure therapy. A 
history of congestive heart failure, coronary artery dis-
ease and lower body mass index were factors associated 
with increased risk  [2] .
 Although most of the cardiac events are controllable, 
some patients do not recover from the cardiac changes 
induced by the therapy and thus can no longer be treated 
with the selected drug  [4] . There is evidence that the 
switch to another multi-kinase inhibitor will not over-
come this situation  [5] . BNP has been shown to be con-
sistently associated with an increased risk of all-cause 
mortality in patients with congestive heart failure, even 
in those cases where no change in the ejection fraction 
can be seen  [6, 7] .
 The only parameter in our patient to reveal the car-
diac function and the dramatic course was BNP in serum 
chemistry. Therapy was restarted after clinical recovery 
of the patient without this parameter being considered. 
We propose to prospectively include BNP as a diagnostic 
tool for early detection of cardiovascular decompensa-
tion in high-risk patients. Future studies concerning the 
relevance of BNP in drug-related cardiotoxicity are ur-
gently needed.
 
 Fig. 1. Left ventricular thrombus with a size of 29.9  ! 32.0 mm 
in subsequent cardial echography (first control after one cycle of 
sunitinib therapy). 
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